?one prior program of chemotherapy for advanced breast cancer and over the total demo, previous exposure to any FGFR inhibitor, significant operation or radiotherapy in just 4 weeks prior to initial dose of research treatment method and having strong inhibitors or inducers of CYP3A4 or CYP2D6. Any of the next cardiac conditions precluded patients m